JP2019522030A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019522030A5 JP2019522030A5 JP2019504740A JP2019504740A JP2019522030A5 JP 2019522030 A5 JP2019522030 A5 JP 2019522030A5 JP 2019504740 A JP2019504740 A JP 2019504740A JP 2019504740 A JP2019504740 A JP 2019504740A JP 2019522030 A5 JP2019522030 A5 JP 2019522030A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- biotin
- hepatic encephalopathy
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 30
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 17
- 229960002685 biotin Drugs 0.000 claims 15
- 235000020958 biotin Nutrition 0.000 claims 15
- 239000011616 biotin Substances 0.000 claims 15
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 229930193140 Neomycin Natural products 0.000 claims 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 2
- 239000000832 lactitol Substances 0.000 claims 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims 2
- 229960003451 lactitol Drugs 0.000 claims 2
- 235000010448 lactitol Nutrition 0.000 claims 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims 2
- 229960000511 lactulose Drugs 0.000 claims 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 2
- 229960000282 metronidazole Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229960004927 neomycin Drugs 0.000 claims 2
- 229960003104 ornithine Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 claims 2
- 229960003040 rifaximin Drugs 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 239000007941 film coated tablet Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305989.2 | 2016-07-29 | ||
| EP16305989.2A EP3275439A1 (en) | 2016-07-29 | 2016-07-29 | Method for treating hepatic encephalopathy |
| PCT/EP2017/069194 WO2018020010A1 (en) | 2016-07-29 | 2017-07-28 | Method for treating hepatic encephalopathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019522030A JP2019522030A (ja) | 2019-08-08 |
| JP2019522030A5 true JP2019522030A5 (enExample) | 2020-09-10 |
Family
ID=56618106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019504740A Ceased JP2019522030A (ja) | 2016-07-29 | 2017-07-28 | 肝性脳症の治療方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10117854B2 (enExample) |
| EP (2) | EP3275439A1 (enExample) |
| JP (1) | JP2019522030A (enExample) |
| KR (1) | KR20190034550A (enExample) |
| AU (1) | AU2017303346A1 (enExample) |
| BR (1) | BR112019001178A2 (enExample) |
| CA (1) | CA3031302A1 (enExample) |
| CY (1) | CY1122348T1 (enExample) |
| DK (1) | DK3319601T3 (enExample) |
| EA (1) | EA201990413A1 (enExample) |
| ES (1) | ES2751154T3 (enExample) |
| HK (1) | HK1254833B (enExample) |
| HR (1) | HRP20191798T1 (enExample) |
| HU (1) | HUE046590T2 (enExample) |
| IL (1) | IL264460B (enExample) |
| LT (1) | LT3319601T (enExample) |
| MA (1) | MA42419B1 (enExample) |
| ME (1) | ME03520B (enExample) |
| PL (1) | PL3319601T3 (enExample) |
| PT (1) | PT3319601T (enExample) |
| RS (1) | RS59300B1 (enExample) |
| SI (1) | SI3319601T1 (enExample) |
| SM (1) | SMT201900628T1 (enExample) |
| WO (1) | WO2018020010A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3275439A1 (en) * | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
| MX387893B (es) * | 2018-04-18 | 2025-03-19 | Alparis Sa De Cv | Nuevas fases solidas de rifaximina. |
| CN116173182A (zh) * | 2023-03-31 | 2023-05-30 | 苏州融析生物科技有限公司 | 醋酸格拉替雷药物组合物在肝硬化预防及治疗药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0788304B2 (ja) * | 1988-03-05 | 1995-09-27 | 三生製薬株式会社 | 高アンモニア血症治療剤 |
| US5814650A (en) * | 1992-09-28 | 1998-09-29 | Lifegroup S.P.A. | Biotin amides able to control glucidic metabolisms under dysmetabolic conditions and relative therapeutical compositions |
| DE20202562U1 (de) * | 2002-02-19 | 2002-05-23 | Orthomol pharmazeutische Vertriebs GmbH, 40764 Langenfeld | Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika |
| US20040219188A1 (en) * | 2003-05-02 | 2004-11-04 | Comer Gail M. | Composition and methods for nutritional management of patients with hepatic disease |
| MX2012007365A (es) | 2009-12-23 | 2012-08-15 | Lupin Ltd | Composiciones farmaceuticas de liberacion lenta de iloperidona. |
| FR2993780B1 (fr) | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
| FR2958166B1 (fr) | 2010-04-06 | 2012-07-13 | Assist Publ Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
| WO2014177286A1 (en) | 2013-04-29 | 2014-11-06 | Assistance Publique - Hopitaux De Paris | Biotin for use in treating x-linked adrenoleukodystrophy |
| EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| CN105614851A (zh) * | 2015-12-27 | 2016-06-01 | 劲膳美生物科技股份有限公司 | 肝性脑病医学配方食品 |
| EP3275439A1 (en) * | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
-
2016
- 2016-07-29 EP EP16305989.2A patent/EP3275439A1/en not_active Ceased
-
2017
- 2017-07-28 SI SI201730093T patent/SI3319601T1/sl unknown
- 2017-07-28 PL PL17742782T patent/PL3319601T3/pl unknown
- 2017-07-28 WO PCT/EP2017/069194 patent/WO2018020010A1/en not_active Ceased
- 2017-07-28 RS RSP20191218 patent/RS59300B1/sr unknown
- 2017-07-28 DK DK17742782T patent/DK3319601T3/da active
- 2017-07-28 EA EA201990413A patent/EA201990413A1/ru unknown
- 2017-07-28 PT PT17742782T patent/PT3319601T/pt unknown
- 2017-07-28 AU AU2017303346A patent/AU2017303346A1/en not_active Abandoned
- 2017-07-28 BR BR112019001178-1A patent/BR112019001178A2/pt not_active IP Right Cessation
- 2017-07-28 ME MEP-2019-267A patent/ME03520B/me unknown
- 2017-07-28 JP JP2019504740A patent/JP2019522030A/ja not_active Ceased
- 2017-07-28 SM SM20190628T patent/SMT201900628T1/it unknown
- 2017-07-28 HR HRP20191798TT patent/HRP20191798T1/hr unknown
- 2017-07-28 KR KR1020197002991A patent/KR20190034550A/ko not_active Withdrawn
- 2017-07-28 MA MA42419A patent/MA42419B1/fr unknown
- 2017-07-28 HK HK18113925.3A patent/HK1254833B/en not_active IP Right Cessation
- 2017-07-28 LT LT17742782T patent/LT3319601T/lt unknown
- 2017-07-28 ES ES17742782T patent/ES2751154T3/es active Active
- 2017-07-28 HU HUE17742782A patent/HUE046590T2/hu unknown
- 2017-07-28 EP EP17742782.0A patent/EP3319601B1/en active Active
- 2017-07-28 CA CA3031302A patent/CA3031302A1/en not_active Abandoned
-
2018
- 2018-03-26 US US15/935,695 patent/US10117854B2/en not_active Expired - Fee Related
- 2018-09-18 US US16/134,144 patent/US10328059B2/en not_active Expired - Fee Related
-
2019
- 2019-01-24 IL IL264460A patent/IL264460B/en active IP Right Grant
- 2019-11-18 CY CY20191101208T patent/CY1122348T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522630A5 (enExample) | ||
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2008520736A5 (enExample) | ||
| JP2013505282A5 (enExample) | ||
| RU2011110765A (ru) | Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения | |
| ATE350040T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| JP2007500154A5 (enExample) | ||
| JP2015038135A5 (enExample) | ||
| JP2018513171A5 (enExample) | ||
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| JP2021509395A5 (enExample) | ||
| JP2019522030A5 (enExample) | ||
| IL310648A (en) | Methods for increasing and/or stabilizing cardiac functions in patients with Fabry disease | |
| CA2570474A1 (en) | A combination composition comprising paracetamol and ibuprofen | |
| JP2018039810A5 (enExample) | ||
| JP2019518022A5 (enExample) | ||
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| JP2020510045A5 (enExample) | ||
| WO2007086079A3 (en) | Sustained release dosage form of phenothiazine derivatives containing channelizer | |
| JP2016505050A5 (enExample) | ||
| BRPI0513598A (pt) | formas de dosagem em comprimidos revestidos de liberação entérica | |
| JP2012505830A5 (enExample) | ||
| HRP20191491T1 (hr) | Biotin za liječenje demijelinizirajućih neuropatija | |
| HRP20191798T1 (hr) | Postupak liječenja jetrene encefalopatije | |
| Goldschmidt et al. | Compound cardiac toxicity of oral erythromycin and verapamil |